Health-care Quality in Semi-intensive Care Units

May 18, 2026 updated by: Mario Negri Institute for Pharmacological Research

Evaluation and Improvement of the Health-care Quality in Semi-intensive Care Units

The main aim of this study is to realize a system of continuous evaluation of healthcare quality in semi-intensive care units.

Study Overview

Status

Recruiting

Conditions

Detailed Description

Collecting data of semi-intensive care units' patients and structural data of hospitals, healthcare quality's indicators will be realized. Starting from those indicators of insuccess, specific for different kinds of patients, it will be possibile to evaluate the general level of care in each singular semi-intensive care unit. The study will least for 5 years, but at the end of every year it will be realized a report of analysis to see the results of each unit.

Study Type

Observational

Enrollment (Estimated)

39000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

all patients hospitalised in a semi-intensive care unit attending the study, during a 5 years period of time (from 1st january 2021, to 31st december 2025)

Description

Inclusion Criteria:

  • all patients hospitalised in a semi-intensive care unit

Exclusion Criteria:

  • None

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Eligible population
All patients admitted in the semi-intensive care units attending the study. Be basing on the average number of patients yearly treated in those units, we expect to have at least 39000 patients during the 5 years of the study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Outcome for stationary patients with high risk of variability
Time Frame: jan 2021 - dec 2025
hospitalization in semi-intensive care unit more than 2 days or transfer to intensive care unit
jan 2021 - dec 2025
Outcome for low gravity patients, with a low organ's damage
Time Frame: jan 2021 - dec 2025
deterioration of the physiopathologic index
jan 2021 - dec 2025
Outcome for semi-intensive patients
Time Frame: jan 2021 - dec 2025
transfer to intensive care unit or hospital mortality
jan 2021 - dec 2025
Outcome for high risk patients
Time Frame: jan 2021 - dec 2025
transfer to intensive care unit or hospital mortality
jan 2021 - dec 2025

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Mario Negri Institute for Pharmacological Research

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2021

Primary Completion (Actual)

December 1, 2022

Study Completion (Estimated)

December 1, 2029

Study Registration Dates

First Submitted

December 15, 2020

First Submitted That Met QC Criteria

December 15, 2020

First Posted (Actual)

December 21, 2020

Study Record Updates

Last Update Posted (Actual)

May 20, 2026

Last Update Submitted That Met QC Criteria

May 18, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • IRFMN_7998

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

Protecting the privacy policy, all the data that underlie results in a publication will be shared. The scientific commettee of the study has to decide the criteria and the best way to share them

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Evaluation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe